Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial

Pancreatic Cancer

Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data
Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data
Early Data Shows BioNTech's Personalized Therapy Safe In Pancreatic Cancer Patients
Early Data Shows BioNTech's Personalized Therapy Safe In Pancreatic Cancer Patients
FDA Removes Clinical Hold On AIM ImmunoTech's Mid-Stage Ampligen Trial In Pancreatic Cancer
FDA Removes Clinical Hold On AIM ImmunoTech's Mid-Stage Ampligen Trial In Pancreatic Cancer
Early Data Shows BioNTech's Personalized Therapy Safe In Pancreatic Cancer Patients
Early Data Shows BioNTech's Personalized Therapy Safe In Pancreatic Cancer Patients
FDA Removes Clinical Hold On AIM ImmunoTech's Mid-Stage Ampligen Trial In Pancreatic Cancer
FDA Removes Clinical Hold On AIM ImmunoTech's Mid-Stage Ampligen Trial In Pancreatic Cancer
AIM ImmunoTech Shares Encouraging Data From Ampligen Study In Pancreatic Cancer
AIM ImmunoTech Shares Encouraging Data From Ampligen Study In Pancreatic Cancer
Amgen Posts Latest Batch of Lumakras Data In Pancreatic Cancer
Amgen Posts Latest Batch of Lumakras Data In Pancreatic Cancer

Pancreatic Cancer Recent News

Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal Studies
Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal Studies
Immix Biopharma Inc's (NASDAQ: IMMX) IMX-110 + anti-PD-1 produced 
ImmunityBio's Shares Jump On Encouraging Data From Pancreatic Cancer Immunotherapy Trial
ImmunityBio's Shares Jump On Encouraging Data From Pancreatic Cancer Immunotherapy Trial
ImmunityBio Inc (NASDAQ: IBRX) has 
Why Did HCW Biologics Shares More Than Double Today?
Why Did HCW Biologics Shares More Than Double Today?
Novocure To Test Its Tumor Treating Fields With Roche's Tecentriq In Pancreatic Cancer
Novocure To Test Its Tumor Treating Fields With Roche's Tecentriq In Pancreatic Cancer
See Why RenovoRx Stock Is Shooting Higher On Tuesday
See Why RenovoRx Stock Is Shooting Higher On Tuesday
Lantern Pharma Secures FDA Orphan Drug Tag For Pancreatic Cancer Candidate
Lantern Pharma Secures FDA Orphan Drug Tag For Pancreatic Cancer Candidate
Novartis' TGFβ Targeted Antibody Secures FDA Orphan Drug Tag For Pancreatic Cancer
Novartis' TGFβ Targeted Antibody Secures FDA Orphan Drug Tag For Pancreatic Cancer
Lantern Pharma Shares Moves Higher On Encouraging Data From Pancreatic Cancer Candidate In Animal Models
Lantern Pharma Shares Moves Higher On Encouraging Data From Pancreatic Cancer Candidate In Animal Models
Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer
Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer
AzurRx BioPharma Stock Gains On Positive MS1819-PERT Combo Data In Pancreatic Insufficiency
AzurRx BioPharma Stock Gains On Positive MS1819-PERT Combo Data In Pancreatic Insufficiency
Galera Therapeutics Stock Surges After Its Lead Candidate Shows Median OS Of 20 Months In Pancreatic Cancer Study
Galera Therapeutics Stock Surges After Its Lead Candidate Shows Median OS Of 20 Months In Pancreatic Cancer Study
XBiotech To Test New Drug Candidate Combined With Approved Treatment In Pancreatic Cancer
XBiotech To Test New Drug Candidate Combined With Approved Treatment In Pancreatic Cancer
AIM ImmunoTech Gets Orphan Drug Tag For Ampligen In Pancreatic Cancer
AIM ImmunoTech Gets Orphan Drug Tag For Ampligen In Pancreatic Cancer
AIM ImmunoTech To Include New Patients In Netherlands Pancreatic Cancer Program
AIM ImmunoTech To Include New Patients In Netherlands Pancreatic Cancer Program
DSMB Recommends Hold On SBP-101 Administration In Early-Stage Metastatic Pancreatic Cancer Study, Shares Tank
DSMB Recommends Hold On SBP-101 Administration In Early-Stage Metastatic Pancreatic Cancer Study, Shares Tank
Merrimack Plummets 30% After Pancreatic Cancer Drug Doesn't Meet Endpoints
Merrimack Plummets 30% After Pancreatic Cancer Drug Doesn't Meet Endpoints
EXCLUSIVE: VolitionRX CEO Talks Trial Updates, Time Until Market
EXCLUSIVE: VolitionRX CEO Talks Trial Updates, Time Until Market
New Drug Could Transform Pancreatic Cancer Treatment
New Drug Could Transform Pancreatic Cancer Treatment
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved